These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 698913)
21. Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck. Presant CA; Ratkin G; Klahr C; Brown C Cancer; 1979 Nov; 44(5):1571-5. PubMed ID: 227570 [TBL] [Abstract][Full Text] [Related]
22. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors. Presant CA; Kolhouse JF; Klahr C Cancer; 1976 Feb; 37(2):620-8. PubMed ID: 1253101 [TBL] [Abstract][Full Text] [Related]
23. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662 [TBL] [Abstract][Full Text] [Related]
24. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
25. [Recent progress in chemotherapy of multiple myeloma]. Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935 [No Abstract] [Full Text] [Related]
26. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
28. M-2 protocol for melphalan-resistant and relapsing multiple myeloma. Cavo M; Galieni P; Tassi C; Gobbi M; Tura S Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830 [TBL] [Abstract][Full Text] [Related]
29. [Chemotherapy of multiple myeloma. Review of the recent trials]. Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807 [No Abstract] [Full Text] [Related]
30. Treatment of multiple myeloma: a randomized study of three different regimens. Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591 [TBL] [Abstract][Full Text] [Related]
31. Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary. Presant CA; Bartolucci A Med Pediatr Oncol; 1983; 11(3):151-3. PubMed ID: 6682929 [TBL] [Abstract][Full Text] [Related]
32. Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Alberts DS; Durie BG; Salmon SE Lancet; 1976 May; 1(7966):926-8. PubMed ID: 57335 [TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Cohen HJ; Silberman HR; Larsen WE; Johnson L; Bartolucci AA; Durant JR Blood; 1979 Oct; 54(4):824-36. PubMed ID: 476303 [No Abstract] [Full Text] [Related]
34. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503 [TBL] [Abstract][Full Text] [Related]
35. Management and prognosis of multiple myeloma. Kyle RA; Elveback LR Mayo Clin Proc; 1976 Dec; 51(12):751-60. PubMed ID: 792581 [TBL] [Abstract][Full Text] [Related]
36. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746 [TBL] [Abstract][Full Text] [Related]
37. Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. Broun GO; Petruska PJ; Hiramoto RN; Cohen HJ Cancer Treat Rep; 1982 Feb; 66(2):237-42. PubMed ID: 7034931 [TBL] [Abstract][Full Text] [Related]
38. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy. Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971 [No Abstract] [Full Text] [Related]
39. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106 [TBL] [Abstract][Full Text] [Related]
40. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)]. Bataille R; Morlock G; Rosenberg F; Sany J; Serre H Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]